Abstract Details

Title Global and Regional Hippocampal Volumes Are Preserved in Neuromyelitis Optica and Do not Seem to Be Related to Cognitive Impairment

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-073

Objective To assess global and regional hippocampal atrophy in neuromyelitis optica (NMO) and its contribution to cognitive dysfunction.

Background The hippocampus is involved in inflammatory neurological diseases. In multiple sclerosis, hippocampal subfields showed different susceptibility to damage, and their atrophy has been related to cognitive deficits.

Design/Methods High-resolution T1-weighted scans were acquired at 3.0T from 28 NMO patients and 20 matched healthy controls (HC). In patients, a neurological examination and a neuropsychological evaluation comprehensive of the Brief Repeatable Battery of Neuropsychological Tests, the Beck Depression Inventory (BDI) and the cognitive impairment index (CII) estimation were also performed. From 3D T1-weighted sequence, cross-sectional pipeline of the Freesurfer6.0 was run to assess global and subregional hippocampal volumes. Normalized volumes of brain (NBV), gray matter (NGMV), white matter (NWMV) and deep GM nuclei were also calculated. Between-group comparisons were adjusted for head size. Partial correlations, corrected for disability and disease duration, were estimated between MRI and neuropsychological measures.

Results NMO patients and HC did not differ for demographic and educational variables. Compared to HC, NMO had lower NBV (p<0.0001), NGMV (p=0.015), left (L)-thalamic (p=0.02) and L-amygdala (p=0.013) volumes, with similar NWMV. No between-group differences emerged in global hippocampal volumes. Compared to HC, patients showed atrophy of the L-hippocampal-fimbria (p=0.013) and right (R)-hippocampal tail (p=0.042). Global CII did not correlate with hippocampal measures, whereas it correlated with NGMV (r=-0.54; p=0.01).13/28 (46%) NMO patients were cognitively impaired (CI). Compared to cognitively preserved (CP), CI patients had lower education (p=0.048) and lower visual acuity (p=0.003), but similar BDI scores. No differences were found in global and regional hippocampal volumes between CI and CP NMO patients.

Conclusions Cognitive impairment affects a significant number of NMO patients and is related to GM atrophy. Differently from other conditions, hippocampal atrophy does not contribute to explain cognitive deficits in these patients.

Authors/Disclosures
Laura Cacciaguerra, MD, PhD (Mayo Clinic) PRESENTER	Dr. Cacciaguerra has nothing to disclose.
Gianna Carla Riccitelli (San Raffaele)	No disclosure on file
Marta Radaelli (Hsr)	Marta Radaelli has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Marta Radaelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Marta Radaelli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Marta Radaelli has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi-Genzyme.
Elisabetta Pagani	Elisabetta Pagani has nothing to disclose.
Maria A. Rocca (Neuroimaging Research Unit)	Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

��ɫ��

��ɫ��